Cardiovascular–Kidney–Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics? DOI Open Access

Victoria Mutruc,

Cristina Bologa, Victoriţa Şorodoc

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(8), С. 2833 - 2833

Опубликована: Апрель 19, 2025

Cardiovascular, renal, and metabolic diseases are pathophysiologically interdependent, posing a significant global health challenge being associated with substantial increase in morbidity mortality. In 2023, the American Heart Association (AHA) defined this complex network of interconnected conditions as cardiovascular–kidney–metabolic (CKM) syndrome. This syndrome is based on common pathophysiological mechanisms, including chronic inflammation, oxidative stress, hyperglycemia insulin resistance, activation renin–angiotensin–aldosterone system (RAAS), neurohormonal dysfunction, which trigger vicious cycle where impairment one organ contributes to progressive deterioration others. An integrated approach these conditions, rather than treating them separate entities, supports holistic management strategy that helps reduce burden public improve patients’ quality life. Existing focuses lifestyle modification, glycemic lipid control, use nephroprotective cardioprotective therapies. narrative review aims synthesize contextualize existing information interactions between systems diagnostic approaches, well provide an overview available therapeutic options.

Язык: Английский

Association between triglyceride glucose-body mass index and the trajectory of cardio-renal-metabolic multimorbidity: insights from multi-state modelling DOI Creative Commons
Haoxian Tang, Jingtao Huang, Xuan Zhang

и другие.

Cardiovascular Diabetology, Год журнала: 2025, Номер 24(1)

Опубликована: Март 21, 2025

Although some studies have examined the association between triglyceride glucose-body mass index (TyG-BMI) and cardiovascular outcomes in cardio-renal-metabolic (CRM) background, none explored its role progression of CRM multimorbidity. In addition, prior research is limited by small sample sizes a failure to account for competitive effects other diseases. this study, data obtained from large-scale, prospective UK Biobank cohort were used. multimorbidity was defined as new-onset ischemic heart disease, type 2 diabetes mellitus, or chronic kidney disease during follow-up. Multivariable Cox regression used analyse independent TyG-BMI each (first, double, triple diseases). The C-statistic calculated model, restricted cubic spline applied assess dose–response relationship. A multi-state model investigate trajectory (from baseline [without disease] first double disease), with disease-specific analyses. This study included 349,974 participants, mean age 56.05 (standard deviation [SD], 8.08), 55.93% whom female. Over median follow-up approximately 14 years, 56,659 (16.19%) participants without developed at least one including 8451 (14.92%) who progressed 789 (9.34%) further disease. crude SD increase associated 47% higher risk 72% 95% C-statistics 0.625, 0.694, 0.764, respectively. Multi-state analysis showed 32% increased new 24% 23% those significantly onset all individual diseases (except stroke) transition Significant interactions also observed, but remained across subgroups. Sensitivity analyses, varying time intervals entering states an expanded definition (including atrial fibrillation, failure, peripheral vascular obesity, dyslipidaemia), confirmed these findings. remarkably influences Incorporating it into prevention management could important public health implications.

Язык: Английский

Процитировано

0

Cardiovascular–Kidney–Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics? DOI Open Access

Victoria Mutruc,

Cristina Bologa, Victoriţa Şorodoc

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(8), С. 2833 - 2833

Опубликована: Апрель 19, 2025

Cardiovascular, renal, and metabolic diseases are pathophysiologically interdependent, posing a significant global health challenge being associated with substantial increase in morbidity mortality. In 2023, the American Heart Association (AHA) defined this complex network of interconnected conditions as cardiovascular–kidney–metabolic (CKM) syndrome. This syndrome is based on common pathophysiological mechanisms, including chronic inflammation, oxidative stress, hyperglycemia insulin resistance, activation renin–angiotensin–aldosterone system (RAAS), neurohormonal dysfunction, which trigger vicious cycle where impairment one organ contributes to progressive deterioration others. An integrated approach these conditions, rather than treating them separate entities, supports holistic management strategy that helps reduce burden public improve patients’ quality life. Existing focuses lifestyle modification, glycemic lipid control, use nephroprotective cardioprotective therapies. narrative review aims synthesize contextualize existing information interactions between systems diagnostic approaches, well provide an overview available therapeutic options.

Язык: Английский

Процитировано

0